PCD regimen (bortezomib + cyclophosphamide + dexamethasone) and VRD regimen (bortezomib + lenalidomide + dexamethasone) in the treatment of patients with newly diagnosed multiple myeloma (NDMM).
Kaufman JL, Shah JJ, Laubach JP, Mitchell AR, Sharp C et al. Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. Blood 2012;120:Abstract 336....
The regimen, known as RVD, combined the drugs Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone, which previously were found to be highly effective in multiple myeloma patients who had relapsed or no longer responded to first-line therapies. New 3-drug combo may effectively treat mul...
“The prognosis for patients with multiple myeloma has improved substantially over the last 10 years,” said ASCO chief medical officer and executive vice president Julie R. Gralow, MD, FACP, FASCO, said during a press briefing. “This trial gives very important inf...
RVd followed by high-dose therapy (HDT), autologous stem cell transplant (ASCT), and consolidation is a SoC regimen for US pts with NDMM. This phase 2, randomized study (GRIFFIN; NCT02874742) evaluated DARA plus RVd (D-RVd) in ASCT-eligible NDMM pts. A 16-pt safety run-in showed no...
PURPOSE: This updated analysis examined survival outcomes after 60 months of follow-up in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with the 3-drug regimen of modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population. METHODS: RVD lite was ...
Exploratory data on bone marrow samples on patients achieving VGPR or better have been collected and analysis for MRD is in process.Conclusions: ModifiedRVD appears to be a well-tolerated and highly effective regimen in the transplant-ineligible population. The ORR rate after up to 4 cycles ...